Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Celltrion : South Korea's Celltrion to begin commercial production of COVID-19 antibody drug

09/08/2020 | 05:28am EST
The logo of Celltrion is seen at company's headquarters in Incheon

South Korea's Celltrion Inc will begin commercial production of its experimental treatment for COVID-19 this month, it said on Tuesday, as it pushes ahead with clinical trials of the antibody drug.

The company said it planned to make a request soon to regulators for emergency use authorisation of the drug, but that it would start mass production - likely to amount to around 1 million doses - before receiving that approval.

The treatment became the country's first COVID-19 antibody drug to be tested on humans after receiving regulatory approval in July for clinical trials.

"We have confirmed the safety of the antiviral antibody drug in the process of the local Phase I clinical trial," Kwon Ki-sung, head of Celltrion's R&D unit, told Reuters.

Celltrion completed a Phase I trial on 32 volunteers in the country and is enrolling an additional nine participants for another Phase I study before moving on to later stage trials, for which regulatory reviews are already underway.

The company is separately conducting overseas human trials of its treatment in the United Kingdom, which will be followed by global second and third stage trials in patients with mild and moderate symptoms.

Shares of Celltrion surged as much as 5.6% on Tuesday, while the broader KOSPI gained 0.7%.

Other companies developing potential COVID-19 treatments include Eli Lilly and Co, Regeneron Pharmaceuticals Inc and AbbVie.

By Sangmi Cha


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION, INC. -0.15% 329500 End-of-day quote.82.04%
KOSPI COMPOSITE INDEX 0.98% 2636.1 Real-time Quote.19.64%
All news about CELLTRION, INC.
11/26CELLTRION : Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment
AQ
11/06CELLTRION, INC. : quaterly earnings release
11/05Celltrion's COVID-19 antibody drug cut recovery time-early study
RE
11/05CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
RE
11/04S.Korea shares extend gains as investors eye tight U.S. election race
RE
11/03S.Korea stocks gain most in nearly 5 months on strong global data
RE
10/27S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
RE
10/26S.Korea shares dip as surging global coronavirus cases dent sentiment
RE
10/26South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
RE
10/25S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
RE
More news
Financials
Sales 2020 1 874 B 1,69 B 1,69 B
Net income 2020 583 B 0,53 B 0,53 B
Net cash 2020 500 B 0,45 B 0,45 B
P/E ratio 2020 78,2x
Yield 2020 0,00%
Capitalization 45 485 B 41 055 M 41 073 M
EV / Sales 2020 24 269x
EV / Sales 2021 21 009x
Nbr of Employees 908
Free-Float 68,3%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 317 578,95 KRW
Last Close Price 340 000,00 KRW
Spread / Highest target 32,4%
Spread / Average Target -6,59%
Spread / Lowest Target -64,1%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.82.04%41 055
MODERNA, INC.680.88%50 267
LONZA GROUP AG56.23%45 319
IQVIA HOLDINGS INC.9.37%32 365
SEAGEN INC.49.05%30 493
IMMUNOMEDICS, INC.315.22%20 324